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Objective: Increased arterial stiffness and sympathovagal imbalance are noted in patients with
obstructive sleep apnea (OSA). It has been thought that continuous positive airway pressure
(CPAP) therapy can have beneficial effects on the vascular function in such cases. However,
it is not yet clear whether the improvement of sympathovagal balance by CPAP might be
related to reduction of the arterial stiffness, independent of changes in the blood pressure.
Methods: In 50 consecutive eligible patients with OSA (apneaehypopnea index 20/hour)
receiving CPAP therapy, the brachial-ankle pulse wave velocity (baPWV), heart rate variability
(LF, HF and LF/HF ratio), baroreceptor sensitivity (BRS), plasma levels of C-reactive protein
(CRP), and endothelial function as assessed by changes in the forearm blood flow before
and after reactive hyperemia (END) were measured before and after 3-months’ CPAP therapy.
Results: Significant decrease of the LF/HF ratio, plasma levels of CRP, baPWV and heart rate
were observed after 3 months’ CPAP therapy. The change in the baPWV following 3-months’
CPAP therapy was significantly correlated with the change in the LF/HF ratio and mean blood
pressure (MBP), but not with that of the BRS, CRP or END after the therapy. Multivariate linear
regression analysis demonstrated a significant correlation between the change in the LF/HF
ratio and that in the baPWV (betaZ 0.305, pZ 0.041), independent of the changes in the
MBP, plasma CRP levels and heart rate.
Conclusions: Improvement of the sympathovagal balance by CPAP therapy may be significantly
related to decreased stiffness of the central to middle-sized arteries, independent of the
changes in the blood pressure and vascular endothelial status.
ª 2010 Elsevier Ltd. All rights reserved.3342 6111; fax: þ81 3 3342 4820.
ed.ac.jp (H. Tomiyama).
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Figure 1 Study protocol of patients examined in the sleep
laboratory between November 2006 and June 2007. Abbrevia-
tions: OSAZ obstructive sleep apnea; AHIZ apneaehypopnea
index; CPAPZ continuous positive airway pressure therapy;
baPWVZ brachial-ankle pulse wave velocity.
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Obstructive sleep apnea (OSA) has been reported to be an
independent risk factor for cardiovascular disease.1,2
Abnormal vascular functions such as increased arterial
stiffness and endothelial dysfunction have been demon-
strated in patients with OSA, and it has been suggested that
the increase in cardiovascular risk in these patients may be
related to these abnormalities.3,4 Increased arterial stiff-
ness is an independent determinant of the cardiovascular
risk. Continuous positive airway pressure (CPAP) therapy,
an established treatment for OSA, has been shown to exert
beneficial effects on the vascular functions.5,6 We showed
increased stiffness of the central to middle-sized arteries in
patients with OSA in a previous study,3 and another study
reported a reduction of the arterial stiffness following CPAP
therapy in OSA patients.6 This reduction of the arterial
stiffness following CPAP therapy is considered to be
attributable, at least in part, to improvements of the
oxidative stress and/or inflammation by CPAP therapy.1,2,7,8
Furthermore, abnormal sympathovagal balance has been
noted frequently in OSA patients, and this imbalance may
directly elevate the blood pressure.9,10 While sym-
pathovagal balance is well known to affect the vascular
tone,11,12 it is not clear whether improvement of the sym-
pathovagal balance by CPAP therapy might also be associ-
ated with a reduction of the arterial stiffness.
The present study was conducted to clarify whether
improvement of the sympathovagal balance by CPAP
therapy may also be associated with a reduction of the
stiffness of the central to middle-sized arteries in patients
with OSA, independent of the changes in the blood pressure.
Materials and methods
Patients and study protocol (Fig. 1)
Consecutive eligible patients were admitted to our insti-
tution between November 2006 and June 2007 for diag-
nostic assessment of sleep disorders.
Among the 76 consecutive participants, 54 were diag-
nosed as having moderate to severe OSA {which is consid-
ered as an indication for CPAP therapy; apneaehypopnea
index (AHI) 20/hour}13e15 and 50 of these patients were
entered in the present study protocol (1 patient was
excluded because of coronary heart disease, 1 patient
because he was under treatment with insulin injections and
2 patients because they were under treatment with beta-
blockers) and followed up at our hospital. Before the
patients were initiated on CPAP therapy, assessments of the
vascular functions {measurement of the brachial-ankle
pulse wave velocity (brachial-ankle PWV), assessment of
changes in the forearm blood flow before and after reactive
hyperemia by strain-gauge plethysmography} and heart
rate variability were conducted, and blood examination
was performed. After 3 months of CPAP therapy, the same
examinations were repeated again. During this 3-month
treatment period, no changes were made in the prescribed
medications. The study was conducted with the approval of
the Ethics Committee of Tokyo Medical University, and the
study was performed in accordance with the guidelines ofthe latest version of the Declaration of Helsinki. Written
informed consent was obtained from each of the patients
prior to his/her participation in the study.
Sleep study
Overnight fully-attended polysomnographic monitoring was
performed with the Alice 4 Sleep System (Respironics,
Inc; Murrysville, PA) in the sleep laboratory. Apnea, hypo-
pnea, sleep stages, and electroencephalographic arousal
were scored according to standard criteria.13e15 AHI was
defined as the number of apneaehypopnea episodes per
hour, and was calculated as the total number of apneae
hypopnea episodes per hour of sleep. The severity of OSA
was classified according the criteria of the American
Academy of Sleep Medicine.14
After the diagnostic polysomnography, the OSA patients
with an AHI of 20/h underwent overnight CPAP titration
(REMStar Auto; Respironics, Inc; Murrysville, PA). The CPAP
level was increased until respiratory events, snores and
oxygen desaturation were eliminated during all stages of
sleep in the supine position. Each patient visited our
outpatient clinic once a month and was encouraged to use
the CPAP device every night. At every visit to our hospital,
the average usage time of CPAP and the AHI under CPAP
treatment were calculated using the software package
included with the CPAP device (Encore Pro, Respironics).
After 3 months of optimal CPAP therapy, the experimental
assessments were repeated.
Measurement of the autonomic functions,
brachial-ankle pulse wave velocity and endothelial
function as assessed by reactive hyperemia
On the morning of the measurement day, the prescribed
drugs were taken by the subjects with a small amount of
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position in a quiet, dark, air-conditioned room (22 C to
25 C) for 5 min. Then, the blood pressure and heart rate
were determined by oscillometric methods (Omron Colin,
Kyoto, Japan). After this measurement, the patients were
allowed to rest in the supine position in the same room.
Then, after the patients had rested for at least 15 min, the
following measurements were conducted; the patients
were instructed to fast for at least 8 h and to abstain from
alcohol, smoking, caffeine and antioxidant vitamins for at
least 12 h prior to the measurements.
The systolic blood pressure and heart rate were recorded
for 10 min in the supine position using arterial tonometry and
electrocardiography (Jentow-7700, Omron Colin, Kyoto,
Japan). These measurements were not controlled for the
respiratory phase. The spontaneous baroreceptor sensitivity
(BRS) and heart rate variability were determined from these
samples using a commercial software (GMview II, Signalysis,
Tokyo, Japan).16 In relation to the assessment of the BRS, all
of the patients exhibited a correlation coefficient of 0.85
between the systolic blood pressure and the R-R interval.
From the samples of the R-R intervals, the high-frequency
power (HF) component, low-frequencypower (LF) component
and the ratio of the LF to HF (LF/HF ratio) were calculated.
After assessment of the autonomic functions, the
brachial-ankle PWV was measured (FORM, Omron Colin,
Kyoto, Japan). The details of the measurement have been
described in a previous report by the authors.17 Briefly,
electrocardiographic electrodes were placed on both wrists,
and a microphone for the phonocardiogram was attached to
the left chest. Electrocardiograms and phonocardiograms
were used to provide timing markers for the device. Occlu-
sion cuffs, which were connected to both the plethysmo-
graphic and oscillometric sensors, were tied around both the
upper arms and ankles while the patients lay in the supine
position. The brachial and post-tibial arterial pressures were
measured by the oscillometric sensor. The brachial and post-
tibial arterial pressure waveforms determined by the
plethysmographic sensor and recorded for 10 sec were
stored. The measurements were conducted after the
subjects had rested for at least 5 min in the supine position.
Then, forearm blood flow was measured by strain-gauge
plethysmography (model EC5R, DE Hokanson, Inc. Bellevue,
WA, USA). A mercury-in-silastic strain gauge that was
electrically calibrated was placed on the thickest part of
the right forearm. A wrist cuff was inflated to 30 mm Hg
above the systolic blood pressure to exclude the hand
circulation from the measurements obtained 1 min before
measurement of the forearm blood flow. The upper arm-
congesting cuff was inflated to 40 mm Hg. The forearm
blood flow was recorded for 7 s and expressed as mL of
blood flow per minute per 100 mL of forearm blood volume.
The forearm vasodilatory response to reactive hyperemia
was evaluated using previously established methods.18
After obtaining the average baseline forearm blood flow
from 2 measurements, the upper arm was compressed by
inflation of a pneumatic tourniquet at a pressure of 30 mm
Hg over the systolic blood pressure for 4.5 min.18 Then, the
forearm blood flow was measured until 120 s after the cuff
deflation; the measurements were taken 30, 60, 90 and
120 s after the cuff deflation. The reactive hyperemia ratio
was calculated as reactive hyperemia divided by thebaseline forearm blood flow: i.e. reactive hyperemia
ratioZ sum of the forearm blood flow obtained at 30, 60,
90 and 120 s after cuff deflation/basal forearm blood flow.
In 22 volunteers, the intra-class correlation coefficient of
reproducibility of the forearm blood flow response to
reactive hyperemia was 0.86.
Laboratory measurements
The serum levels of low-density lipoprotein cholesterol,
high-density lipoprotein cholesterol, triglycerides and
creatinine, and the plasma level of glucose were measured
enzymatically in the subjects after they had fasted over-
night. The plasma levels of high-sensitive C-reactive
protein (CRP) were measured by immunonephelometry
using a validated assay method (Dade Boehring Holding
GmbH, Liederbach, Germany).
Statistical analysis
All the data, including those presented in the tables, were
expressed as means SD. The significances of the differ-
ences in the variables measured between the start of the
study and after 3 months of CPAP therapy were determined
using Wilcoxon’s t test for paired variables. The differences
in the values before and after 3 months of CPAP therapy
were calculated as the percent delta changes: (values after
3 months of CPAP therapy minus those before CPAP
therapy) divided by the values before CPAP therapy x 100.
Correlations among the variables were assessed by both
univariate linear regression analysis and multivariate linear
regression analyses. P values of less than 0.05 were
considered to denote statistically significant differences.
The statistical analyses were performed using the SPSS
software package (SPSS Inc., J11.0, Chicago, IL).
Results
A total of 50patients entered into thepresent studyprotocol.
Table 1 shows the changes in the variables before and after 3
months of CPAP therapy. CPAP therapy for 3 months was
followed by a significant decrease of the LF/HF ratio, plasma
level of CRP, brachial-ankle PWV and the heart rate. In the
univariate linear regression analysis performed to assess the
relationship of the percent delta change of the brachial-
ankle PWV following 3-months’ CPAP therapy with the
changes in the other variables, a significant positive corre-
lation was found between the percent delta change of the
brachial-ankle PWV and that of the LF/HF ratio (rZ 0.33,
pZ 0.02) and mean blood pressure (rZ 0.66, p< 0.01), but
not those of other variables. Multivariate linear regression
analysis demonstrated that the percent delta change of the
brachial-ankle PWV after 3 months of CPAP therapy was
significantly related to that of the LF/HF, independent of the
change of the mean blood pressure (Table 2).
Discussion
To the best of our knowledge, the present study is the first
to evaluate the correlation between the change in the
sympathovagal balance and that of the stiffness of the
Table 1 Changes in the clinical characteristics after
3-months’ CPAP therapy.
Variables Baseline After 3 months
of CPAP
P value
No. of subjects 50
Age, yr 54 10
Gender
(male/female)
45/5
BMI, kg/m2 27.4 3.4 27.5 3.6 0.53
Smokers {n (%)} 25 (50) 25 (50)
SBP (mmHg) 129 14 129 16 0.78
DBP (mmHg) 80 11 80 10 0.63
HR (beats/min) 75 13 66 9 <0.001
AHI (events/h) 53.6 22.1
Lowest SpO2 (%) 77 9
ESS 10 4
TC (mg/dL) 204 32 203 30 0.44
TG (mg/dL) 199 161 208 167 0.06
HDL (mg/dL) 48 12 50 12 0.13
FPG (mg/dL) 100 25 99 23 0.25
Crnn (mg/dL) 0.81 0.18 0.79 0.17 0.06
CRP (mg/L) 1.1 1.5 0.8 0.8 0.036
baPWV (m/sec) 15.4 0.3 14.5 0.3 0.001
END 15.7 3.6 16.5 6.2 0.36
LF (ms2) 474 485 522 598 0.82
HF (ms2) 210 280 256 372 0.83
LF/HF 4.6 3.9 3.4 2.4 0.036
BRS (msec/mmHg) 8.1 4.3 9.7 4.5 0.15
Medication
CCB 14 14
ARB 7 7
ACEi 13 13
Diuretics 2 2
Statin 12 12
Med for DM 5 5
Abbreviations: BMIZ body mass index; SBPZ systolic blood
pressure; DBPZ diastolic blood pressure; HRZ heart rate;
AHIZ apneaehypopnea index; ESSZ Epworth sleepiness scale;
TCZ serum total cholesterol; HDLZ serum high density lipo-
protein cholesterol; TGZ serum triglycerides; FPGZ fasting
plasma glucose; CrnnZ serum levels of creatinine;
CRPZ plasma levels of C-reactive protein; baPWVZ brachial-
ankle pulse wave velocity; ENDZ endothelial function assessed
by changes in the forearm blood flow before and after reactive
hyperemia; LFZ low-frequency power component of the heart
rate variability; HFZ high-frequency power component of heart
rate variability; LF/HFZ low-frequency power component/
high-frequency power component ratio of heart rate variability;
BRSZ baroreceptor sensitivity; MedicationZ number of
patients on medication; CCBZ calcium channel blocker;
ARBZ angiotensin II receptor blocker; ACEiZ angiotensin-con-
verting enzyme inhibitor; Med for DMZ oral medication for
diabetes mellitus.
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patients with moderate to severe OSA.
Arterial stiffness has been classified as functional stiff-
ness and structural stiffness.19,20 The former is mainly
derived from the arterial wall tension and arterial wall
tone.11,19e21 Blood pressure affects the arterial wall tension,
and vasoactive substances and sympathovagal activityinfluence the arterial wall tone.11,19e21 On the other hand,
the latter is mainly derived from degenerative changes of
the arterial wall, such as the degradation of elastin fibers,
proliferation of collagen fibers and vascular smooth muscle
cell hypertrophy.19,20 A relatively short period of CPAP
therapy (less than 4 months) has been shown to improve the
carotid-femoral PWV,22 a marker of central arterial stiff-
ness, as well as the brachial-ankle PWV6; therefore, it was
considered that this therapy might also improve functional
arterial stiffness. While CPAP therapy decreases the blood
pressure level,23 Kitahara et al. demonstrated that this
therapy decreased the brachial-ankle PWVwithout affecting
the blood pressure.6 Even so, the precise mechanisms
underlying the pressure-independent reduction of the
stiffness of the central to middle-sized arteries brought
about after CPAP therapy still remain unclear.
Blood pressure has been demonstrated as one of the
major determinants of arterial stiffness,17,19,20 therefore,
the change of the brachial-ankle PWV following CPAP
therapy would be expected to be significantly correlated
with the change of the mean blood pressure. However, in
the present study, CPAP therapy was followed by a reduc-
tion of the brachial-ankle PWV without any significant
reduction of the blood pressure. These findings suggest
a pressure-independent effect of CPAP therapy on the
arterial stiffness, and one of the plausible mechanisms
underlying such an effect might be reduction of the arterial
tone. Thus, the autonomic nervous system (i.e., sym-
pathovagal balance) may have some major roles in the
regulation of arterial stiffness.11,21 In the present study,
the sympathovagal balance was assessed by assessment of
the heart rate variability. In the analysis of heart rate
variability, the LF component is mainly correlated with the
sympathetic efferent activity, the HF component is mainly
correlated with the vagal activity, and the LF/HF ratio
serves as an index of the sympathovagal balance.24e26
Huang et al demonstrated increase of the LF/HF ratio by
hypoxia,27 therefore, the value of the LF/HF ratio in the
present study subjects was higher than that in healthy
subjects28e30; the results of the present study wherein
CPAP therapy decreased the LF/HF ratio was consistent
with this. Similar findings have been demonstrated in
another study.29 Then, in the present study, multivariate
linear regression analysis demonstrated that the changes in
the LF/HF ratio by CPAP therapy were positively correlated
with the changes in brachial-ankle PWV, independent of the
changes in the mean blood pressure. Therefore, the
changes of the sympathovagal balance occurring following
CPAP therapy might be correlated, at least in part, with the
reduction of arterial stiffness of the central to middle-sized
arteries in patients with OSA.
Endothelial function affects the arterial stiffness via
various endothelium-derived vasoactive substances.19,20 In
the present study, endothelial function was assessed by the
changes in the forearm blood flow response to reactive
hyperemia, and nitric oxide (NO), endothelium-derived
hyperpolarization factors (EDHF) and/or adenosine are
thought to affect this response.31,32 In addition, we
measured the plasma levels of CRP as a marker of vascular
endothelial inflammation.33 While CPAP therapy signifi-
cantly reduced the plasma levels of CRP in the present
study, it did not improve the endothelial function. The
Table 2 Multivariate Linear Regression Analysis to Assess the Relationship of Percent Delta Changes by CPAP Therapy in
brachial-ankle PWV with those in LF/HF and MBP. Dependent variableZ Percent delta changes in brachial-ankle pulse wave
velocity by continuous positive airway pressure therapy. Total R-squareZ 0.483.
Independent
variable
Non-standardization
coefficient (SE)
Standardization
coefficient
t-Value p-Value
perdl LF/HF 4.333 102 (0.020) 0.305 2.124 0.041
perdl MBP 57.148 (16.356) 0.501 3.494 0.001
perdl CRP 4.881 103 (0.006) 0.104 0.825 0.415
perdl HR 4.965 102 (0.100) 0.065 0.497 0.622
Abbreviations: SEZ standard error; perdlZ percent delta changes before and after 3 months of CPAP therapy; MBPZmean blood
pressure.
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showed no significant relationship with the changes in the
brachial-ankle PWV following the therapy. Thus, the
present study results suggested that the improvement of
the vascular endothelial status by CPAP therapy was not
a major determinant of the stiffness of the central to
middle-sized arteries.
Study limitations
The present study had some study limitations: 1. Increased
arterial stiffness, especially of the central artery, is an
independent risk factor for cardiovascular disease.19,20
While several studies have demonstrated that sympathetic
activation increases the central arterial stiffness,34,35 we
did not clarify the independent correlation of the change of
the sympathovagal balance following CPAP therapy to that
of the carotid-femoral PWV, a gold standard for assessment
of the central arterial stiffness in the present study36; 2.
The relationships between oxidative stress and arterial
stiffness are controversial,37 and we did not evaluate the
effect of CPAP therapy on this relationship in this study; 3.
In the present study protocol, nitroglycerine forearm blood
flow response was not obtained and the respiration was not
controlled for measurement of the autonomic nervous
function; 4. At our institution, OSA patients with coronary
heart disease and/or heart failure are managed at the
outpatients department for coronary heart disease or heart
failure. Therefore, none of the present study subjects had
clinical manifestations of cardiovascular disease. Confir-
mation of the relationship between the changes in the
sympathovagal balance and those of the arterial stiffness
following CPAP therapy in subjects with clinical manifes-
tations of cardiovascular disease is proposed.
Conclusions
In patientswithOSA,CPAP therapyexertedbeneficial effects
on parameters of the heart rate variability and on the
brachial-ankle PWV. Furthermore, the improvements in both
parameters were significantly correlated, independent of
the changes in the blood pressure, endothelial function and
plasma levels of CRP. Thus, the change of the sympathovagal
balance byCPAP therapymaybe significantly correlatedwith
the decreased stiffness of the central to middle-sized
arteries, independent of the changes in the blood pressure
and vascular endothelial status.Conflict of interest statement
The authors have no conflict of interests to declare.
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